AC
LRMR icon

AXQ Capital’s Larimar Therapeutics LRMR Stock Holding History

AXQ Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,973
Closed -$238K – 1188
2026
Q1 		$238K Buy
52,973
+35,318
+200% +$141K 0.03% 679
2025
Q4 		$67.3K Sell
17,655
-20,116
-53% -$78.2K 0.02% 680
2025
Q3 		$122K Buy
37,771
+17,918
+90% +$67.2K 0.05% 501
2025
Q2 		$57.4K Buy
+19,853
New +$46K 0.02% 537
2025
Q1 		– Sell
-23,578
Closed -$91.2K – 594
2024
Q4 		$91.2K Buy
+23,578
New +$156K 0.04% 381

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

AXQ Capital's LRMR Position: Q2 2026 in Review

AXQ Capital sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 52,973 shares — an estimated $238K sold.

AXQ Capital first reported a position in LRMR in Q4 2024 and held it in 5 quarters. The position peaked at $238K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • AXQ Capital reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • AXQ Capital sold 52,973 Larimar Therapeutics shares in Q2 2026, an estimated $238K.
  • AXQ Capital first reported a position in Larimar Therapeutics in Q4 2024 and held it in 5 quarters.
  • AXQ Capital's Larimar Therapeutics position peaked at $238K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.